Top

Published in:

Open Access 01-12-2024 | NSCLC | Review

Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer

Authors: Yutao Li, Amit Sharma, Ingo G.H. Schmidt-Wolf

Published in: Molecular Cancer | Issue 1/2024

Abstract

Undeniably, cancer immunotherapies have expanded the spectrum of cancer treatment, however, some patients do not respond to immunotherapies. This scenario is no different for lung cancer, whose two main types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), still pose a serious clinical challenge. Adoptive T-cell therapies (ATC), which primarily include cytokine-induced killer (CIK) cell therapy, chimeric antigen receptor T-cell (CAR T-cell) therapy and γδ-T-cell therapy, strengthen the patient’s immune system in combating cancer. Combining ATC with immune checkpoint inhibitors (ICI) further enhances the effectiveness of this approach to eradicate cancer. With a particular emphasis on CIK cell therapy, which recently completed 30 years, we highlight the role of the PD-1/PD-L1 axis in NSCLC and SCLC. Besides, we provide insights into the potential synergies of PD-1/PD-L1 inhibitors with adoptive T-cell immunotherapy in reshaping the treatment paradigm for lung cancer.

Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell Lung cancer. Nature. 2018;553:446–54.CrossRefPubMed

Noone AM, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2015. Bethesda, MD: National Cancer Institute; 2018. http://seer.cancer.gov/archive/csr/1975_2012/.

Hardtstock F, Myers D, Li T, et al. Real-world treatment and survival of patients with advanced non-small cell Lung Cancer: a German retrospective data analysis. BMC Cancer. 2020;20:260. https://doi.org/10.1186/s12885-020-06738-z.CrossRefPubMedPubMedCentral

Kahnert K, Kauffmann-Guerrero D, Huber RM. SCLC-state of the art and what does the future have in store? Clin Lung Cancer. 2016;17:325–33. https://doi.org/10.1016/j.cllc.2016.05.014.CrossRefPubMed

Karachaliou N, Pilotto S, Lazzari C, et al. Cellular and molecular biology of small cell Lung cancer: an overview. Transl Lung Cancer Res. 2016;5:2–15. https://doi.org/10.3978/j.issn.2218-6751.2016.01.02.CrossRefPubMedPubMedCentral

Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus Docetaxel in previously treated patients with advanced non-small-cell Lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35:3924–33. https://doi.org/10.1200/JCO.2017.74.3062.CrossRefPubMedPubMedCentral

Lu S, Wang J, Cheng Y, et al. Nivolumab versus Docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell Lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). Lung Cancer. 2021;152:7–14. https://doi.org/10.1016/j.lungcan.2020.11.013.CrossRefPubMed

Hellmann MD, Callahan MK, Awad MM, et al. Tumor mutation burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small cell Lung cancer. Cancer Cell. 2018;33:853–861e4. https://doi.org/10.1016/j.ccell.2018.04.001.CrossRefPubMedPubMedCentral

10.

Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21. https://doi.org/10.1038/nature12477.CrossRefPubMedPubMedCentral

11.

Byers LA, Rudin CM. Small cell Lung cancer: where do we go from here? Cancer. 2015;121:664–72. https://doi.org/10.1002/cncr.29098.CrossRefPubMed

12.

Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-related adverse effects of Immune Checkpoint inhibitors. Rev JAMA Oncol. 2016;2:1346–53. https://doi.org/10.1001/jamaoncol.2016.1051.CrossRef

13.

Schmidt-Wolf IG, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human Lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139–49. https://doi.org/10.1084/jem.174.1.139.CrossRefPubMed

14.

Pievani A, Borleri G, Pende D, et al. Dual-functional capability of CD3⁺CD56⁺ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood. 2011;118:3301–10. https://doi.org/10.1182/blood-2011-02-336321.CrossRefPubMed

15.

Zhang Y, Schmidt-Wolf IGH. Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. J Cell Physiol. 2020;235:9291–303. https://doi.org/10.1002/jcp.29827.CrossRefPubMed

16.

Qu J, Mei Q, Chen L, et al. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell Lung cancer (NSCLC): current status and future perspectives. Cancer Immunol Immunother. 2021;70:619–31. https://doi.org/10.1007/s00262-020-02735-0.CrossRefPubMed

17.

Xu Y, Xiang Z, Alnaggar M, et al. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or Liver cancer. Cell Mol Immunol. 2021;18:427–39. https://doi.org/10.1038/s41423-020-0515-7.CrossRefPubMed

18.

Li HY, McSharry M, Bullock B, et al. The Tumor Microenvironment regulates sensitivity of Murine Lung Tumors to PD-1/PD-L1 antibody blockade. Cancer Immunol Res. 2017;5:767–77. https://doi.org/10.1158/2326-6066.CIR-16-0365.CrossRefPubMedPubMedCentral

19.

Rock JR, Randell SH, Hogan BL. Airway basal stem cells: a perspective on their roles in epithelial homeostasis and remodeling. Dis Model Mech. 2010;3:545–56. https://doi.org/10.1242/dmm.006031.CrossRefPubMedPubMedCentral

20.

George PJ, Banerjee AK, Read CA, et al. Surveillance for the detection of early Lung cancer in patients with bronchial dysplasia. Thorax. 2007;62:43–50. https://doi.org/10.1136/thx.2005.052191.CrossRef

21.

Stevens TP, McBride JT, Peake JL, et al. Cell proliferation contributes to PNEC hyperplasia after acute airway injury. Am J Physiol. 1997;272:L486–93. https://doi.org/10.1152/ajplung.1997.272.3.L486.CrossRefPubMed

22.

Reynolds SD, Hong KU, Giangreco A, et al. Conditional clara cell ablation reveals a self-renewing progenitor function of pulmonary neuroendocrine cells. Am J Physiol Lung Cell Mol Physiol. 2000;278:L1256–63. https://doi.org/10.1152/ajplung.2000.278.6.L1256.CrossRefPubMed

23.

Spella M, Lilis I, Pepe MA, et al. Club cells form lung adenocarcinomas and maintain the alveoli of adult mice. Elife. 2019;8:e45571. https://doi.org/10.7554/eLife.45571.CrossRefPubMedPubMedCentral

24.

Miyata-Morita K, Morita S, Matsutani N, et al. Frequent appearance of club cell (Clara cell)-like cells as a histological marker for ALK-positive lung adenocarcinoma. Pathol Int. 2019;69:688–96. https://doi.org/10.1111/pin.12864.CrossRefPubMed

25.

Chen Y, Toth R, Chocarro S, et al. Club cells employ regeneration mechanisms during lung tumorigenesis. Nat Commun. 2022;13:4557. https://doi.org/10.1038/s41467-022-32052-2.CrossRefPubMedPubMedCentral

26.

Hardavella G, George R, Sethi T. Lung Cancer Stem Cells-Characteristics, phenotype. Transl Lung Cancer Res. 2016;5:272–9. https://doi.org/10.21037/tlcr.2016.02.01.CrossRefPubMedPubMedCentral

27.

Raniszewska A, Polubiec-Kownacka M, Rutkowska E, et al. PD-L1 expression on Lung Cancer Stem cells in metastatic lymph nodes Aspirates. Stem Cell Rev Rep. 2019;15:324–30. https://doi.org/10.1007/s12015-018-9860-7.CrossRefPubMed

28.

Raniszewska A, Vroman H, Dumoulin D, et al. PD-L1⁺ Lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients. Cancer Immunol Immunother. 2021;70:453–61. https://doi.org/10.1007/s00262-020-02648-y.CrossRefPubMed

29.

Murthy V, Katzman DP, Tsay JJ, et al. Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell Lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: a pilot study. Lung Cancer. 2019;137:94–9. https://doi.org/10.1016/j.lungcan.2019.08.008.CrossRefPubMed

30.

Zhu S, Luo Z, Li X, Han X, Shi S, Zhang T. Tumor-associated macrophages: role in tumorigenesis and immunotherapy implications. J Cancer. 2021;12:54–64. https://doi.org/10.7150/jca.49692.CrossRefPubMedPubMedCentral

31.

Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21:28. https://doi.org/10.1186/s12943-021-01489-2.CrossRefPubMedPubMedCentral

32.

Liu Y, Zugazagoitia J, Ahmed FS, et al. Immune Cell PD-L1 colocalizes with macrophages and is Associated with Outcome in PD-1 pathway blockade therapy. Clin Cancer Res. 2020;26:970–7. https://doi.org/10.1158/1078-0432.CCR-19-1040.CrossRefPubMed

33.

Shinchi Y, Ishizuka S, Komohara Y, et al. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma. Cancer Immunol Immunother. 2022;1–17. https://doi.org/10.1007/s00262-022-03187-4.

34.

Watanabe H, Ohashi K, Nishii K, et al. A long-term response to Nivolumab in a case of PD-L1-negative lung adenocarcinoma with an EGFR mutation and surrounding PD-L1-positive tumor-associated macrophages. Intern Med. 2019;58(20):3033–7. https://doi.org/10.2169/internalmedicine.2875-19.CrossRefPubMedPubMedCentral

35.

Shima T, Shimoda M, Shigenobu T, et al. Infiltration of tumor-associated macrophages is involved in Tumor programmed death-ligand 1 expression in early lung adenocarcinoma. Cancer Sci. 2020;111:727–38. https://doi.org/10.1111/cas.14272.CrossRefPubMedPubMedCentral

36.

Yang Z, Peng Y, Guo W, et al. PD-L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell Lung cancer. Thorac Cancer. 2021;12:1743–51. https://doi.org/10.1111/1759-7714.13989.CrossRefPubMedPubMedCentral

37.

Zhou Q, Liang J, Yang T, et al. Carfilzomib modulates Tumor microenvironment to potentiate immune checkpoint therapy for cancer. EMBO Mol Med. 2022;14:e14502. https://doi.org/10.15252/emmm.202114502.CrossRefPubMed

38.

Liu M, Tong Z, Ding C, et al. Transcription factor c-Maf is a checkpoint that programs macrophages in Lung cancer. J Clin Invest. 2020;130:2081–96. https://doi.org/10.1172/JCI131335.CrossRefPubMedPubMedCentral

39.

Koto S, Chihara N, Akatani R, et al. Transcription factor c-Maf promotes immunoregulation of programmed cell death 1-Expressed CD8⁺ T cells in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9(4):e1166. https://doi.org/10.1212/NXI.0000000000001166.CrossRefPubMedPubMedCentral

40.

Gusak A, Fedorova L, Lepik K, et al. Immunosuppressive microenvironment and efficacy of PD-1 inhibitors in Relapsed/Refractory classic Hodgkin Lymphoma: Checkpoint molecules Landscape and Macrophage populations. Cancers (Basel). 2021;13(22):5676. https://doi.org/10.3390/cancers13225676.CrossRefPubMed

41.

Mariathasan S, Turley SJ, Nickles D, et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–8. https://doi.org/10.1038/nature25501.CrossRefPubMedPubMedCentral

42.

Li L, Wei JR, Dong J, et al. Laminin γ2–mediating T cell exclusion attenuates response to anti–PD-1 therapy. Sci Adv. 2021;7:eabc8346. https://doi.org/10.1126/sciadv.abc8346.CrossRefPubMedPubMedCentral

43.

Reuben A, Zhang J, Chiou SH, et al. Comprehensive T cell repertoire characterization of non-small cell Lung cancer. Nat Commun. 2020;11:603. https://doi.org/10.1038/s41467-019-14273-0.CrossRefPubMedPubMedCentral

44.

Kamphorst AO, Pillai RN, Yang S. Proliferation of PD-1⁺ CD8 T cells in peripheral blood after PD-1-targeted therapy in Lung cancer patients. PNAS. 2017;114:4993–8. https://doi.org/10.1073/pnas.1705327114.CrossRefPubMedPubMedCentral

45.

Zheng Y, Han L, Chen Z, et al. PD-L1+CD8+ T cells enrichment in Lung cancer exerted regulatory function and tumor-promoting tolerance. iScinece. 2022;25:103785. https://doi.org/10.1016/j.isci.2022.103785.CrossRef

46.

Bailly C, Thuru X, Quesnel B. Soluble programmed death Ligand-1 (sPD-L1): A Pool of circulating proteins implicated in Health and Diseases. Cancers. 2021;13(12):3034. https://doi.org/10.3390/cancers13123034.CrossRefPubMedPubMedCentral

47.

Sagawa R, Sakata S, Gong B, et al. Soluble PD-L1 works as a decoy in Lung cancer immunotherapy via alternative polyadenylation. JCI Insight. 2022;7:e153323. https://doi.org/10.1172/jci.insight.153323.CrossRefPubMedPubMedCentral

48.

Lu F, Dong Y, Li Q, Wang M. The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance. Comput Math Methods Med. 2022; 2022: 8375349. https://doi.org/10.1155/2022/8375349.

49.

Yuan Y, He Y, Wang X, et al. Investigation on the effects of soluble programmed death-1 (sPD-1) enhancing anti-tumor immune response. J Huazhong Univ Sci Technolog Med Sci. 2004;24(6):531–4. https://doi.org/10.1007/bf02911345.CrossRefPubMed

50.

He L, Zhang G, He Y, et al. Blockade of B7-H1 with sPD-1 improves immunity against Murine Hepatocarcinoma. Anticancer Res. 2005;25(5):3309–13.PubMed

51.

Meyo MT, Jouinot A, Giroux-Leprieur E, et al. Predictive value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-small Cell Lung Cancer: a case-control study. Cancers. 2020;12:473. https://doi.org/10.3390/cancers12020473.CrossRef

52.

Ohkuma R, Ieguchi K, Watanabe M, et al. Increased plasma soluble PD-1 concentration correlates with Disease Progression in patients with Cancer treated with Anti-PD-1 antibodies. Biomedicines. 2021;9(12):1929. https://doi.org/10.3390/biomedicines9121929.CrossRefPubMedPubMedCentral

53.

Yang Q, Chen M, Gu J, et al. Novel biomarkers of dynamic blood PD-L1 expression for Immune checkpoint inhibitors in Advanced Non-small-cell Lung Cancer patients. Front Immunol. 2021;12:665133. https://doi.org/10.3389/fimmu.2021.665133.CrossRefPubMedPubMedCentral

54.

Ferrarini M, Pupa SM, Zocchi MR, et al. Distinct pattern of HSP72 and monomeric laminin receptor expression in human Lung Cancers infiltrated by gamma/delta T lymphocytes. Int J Cancer. 1994;57(4):486–90. https://doi.org/10.1002/ijc.2910570408.CrossRefPubMed

55.

Ferrarini M, Heltal S, Chiesa G, et al. Vδ1⁺ Gamma/Delta T Lymphocytes Infiltrating Human Lung Cancer Express the CD8α/α Homodimer. Scand J Immunol. 1994;40(3):363–7. https://doi.org/10.1111/j.1365-3083.1994.tb03475.x.CrossRefPubMed

56.

Zocchi MR, Ferrarini M, Rugarli C. Selective lysis of the autologous Tumor by delta TCS1⁺ gamma/delta⁺ tumor-infiltrating lymphocytes from human lung carcinomas. Eur J Immunol. 1990;20(12):2685–9. https://doi.org/10.1002/eji.1830201224.CrossRefPubMed

57.

Wu Y, Biswas D, Usaite I, et al. A local human Vδ1 T cell population is associated with survival in nonsmall-cell Lung cancer. Nat Cancer. 2022;3(6):696–709. https://doi.org/10.1038/s43018-022-00376-z.CrossRefPubMedPubMedCentral

58.

Tosolini M, Pont F, Poupot M, et al. Assessment of tumor-infiltrating TCRV γ 9V δ 2 γδ lymphocyte abundance by deconvolution of human cancers microarrays. Oncoimmunology. 2017;6(3):e1284723. https://doi.org/10.1080/2162402X.2017.1284723.CrossRefPubMedPubMedCentral

59.

Cazzetta V, Bruni E, Terzoli S, et al. NKG2A expression identifies a subset of human Vδ2 T cells exerting the highest antitumor effector functions. Cell Rep. 2021;37(3):109871. https://doi.org/10.1016/j.celrep.2021.109871.CrossRefPubMed

60.

George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell Lung cancer. Nature. 2015;524:47–53. https://doi.org/10.1038/nature14664.CrossRefPubMedPubMedCentral

61.

Acheampong E, Abed A, Morici M, et al. Tumour PD-L1 expression in small-cell Lung Cancer: a systematic review and Meta-analysis. Cells. 2020;9:2393. https://doi.org/10.3390/cells9112393.CrossRefPubMedPubMedCentral

62.

Hamilton G, Rath B. Immunotherapy for small cell Lung cancer: mechanisms of resistance. Expert Opin Biol Ther. 2019;19:423–32. https://doi.org/10.1080/14712598.2019.1592155.CrossRefPubMed

63.

Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell Lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883–95. https://doi.org/10.1016/S1470-2045(16)30098-5.CrossRefPubMed

64.

Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell Lung cancer: results from the phase ib KEYNOTE-028 study. J Clin Oncol. 2017;35:3823–9. https://doi.org/10.1200/JCO.2017.72.5069.CrossRefPubMed

65.

Kursunel MA, Taskiran EZ, Tavukcuoglu E, et al. Small cell Lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes. Cancer Immunol Immunother. 2022;71:445–59. https://doi.org/10.1007/s00262-021-02998-1.CrossRefPubMed

66.

Ouadah Y, Rojas ER, Riordan DP, et al. A subpopulation of pulmonary neuroendocrine cells are reserve stem cells regulated by the Tumor suppressors rb, p53, and Notch. Cell. 2019;179:403–416e23. https://doi.org/10.1016/j.cell.2019.09.010.CrossRefPubMedPubMedCentral

67.

Rudin CM, Poirier JT, Byers LA, et al. Molecular subtypes of small cell Lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289–97. https://doi.org/10.1038/s41568-019-0133-9.CrossRefPubMedPubMedCentral

68.

Lee BS, Park DI, Lee DH, et al. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. Biochem Biophys Res Commun. 2017;491:493–9. https://doi.org/10.1016/j.bbrc.2017.07.007.CrossRefPubMed

69.

Wang G, Lu X, Dey P, et al. Targeting YAP-dependent MDSC infiltration impairs Tumor progression. Cancer Discov. 2016;6:80–95. https://doi.org/10.1158/2159-8290.CD-15-0224.CrossRefPubMed

70.

Shibata M, Ham K, Hoque MO. A time for YAP1: tumorigenesis, immunosuppression and targeted therapy. Int J Cancer. 2018;143:2133–44. https://doi.org/10.1002/ijc.31561.CrossRefPubMedPubMedCentral

71.

Horie M, Saito A, Ohshima M, et al. YAP and TAZ modulate cell phenotype in a subset of small cell Lung cancer. Cancer Sci. 2016;107:1755–66. https://doi.org/10.1111/cas.13078.CrossRefPubMedPubMedCentral

72.

Roper N, Velez MJ, Chiappori A, et al. Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell Lung cancer. Nat Commun. 2021;12:3880. https://doi.org/10.1038/s41467-021-24164-y.CrossRefPubMedPubMedCentral

73.

Saito H, Tenjin Y, Yamada T, et al. The role of YAP1 in small cell Lung cancer. Hum Cell. 2022;35:628–38. https://doi.org/10.1007/s13577-022-00669-6.CrossRefPubMed

74.

Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different Disease. Nat Rev Cancer. 2007;7:778–90. https://doi.org/10.1038/nrc2190.CrossRefPubMed

75.

Lamberti G, Sisi M, Andrini E, et al. The mechanisms of PD-L1 Regulation in Non-small-cell Lung Cancer (NSCLC): which are the involved players? Cancers. 2020;12:3129. https://doi.org/10.3390/cancers12113129.CrossRefPubMedPubMedCentral

76.

Re MD, Cucchiara F, Rofi E, et al. A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. Cancer Immunol Immunother. 2021;70(6):1667–78. https://doi.org/10.1007/s00262-020-02810-6.CrossRefPubMed

77.

Dhakar R, Dakal TC, Sharma A. Genetic determinants of Lung cancer: understanding the oncogenic potential of somatic missense mutations. Genomics. 2022;114(4):110401. https://doi.org/10.1016/j.ygeno.2022.110401.CrossRefPubMed

78.

Shinohara T, Taniwaki M, Ishida Y, et al. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics. 1994;23:704–6. https://doi.org/10.1006/geno.1994.1562.CrossRefPubMed

79.

Jiang X, Wang J, Deng X, et al. Role of the Tumor microenvironment in PD-L1/PD-1-mediated Tumor immune Escape. Mol Cancer. 2019;18:10. https://doi.org/10.1186/s12943-018-0928-4.CrossRefPubMedPubMedCentral

80.

Wartewig T, Kurgyis Z, Keppler S, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017;552:121–5. https://doi.org/10.1038/nature24649.CrossRefPubMedPubMedCentral

81.

Patsoukis N, Brown J, Petkova V, et al. Selective effects of PD-1 on akt and ras pathways regulate Molecular Components of the cell cycle and inhibit T cell proliferation. Sci Signal. 2012;5:ra46. https://doi.org/10.1126/scisignal.2002796.CrossRefPubMedPubMedCentral

82.

Gulati P, Rühl J, Kannan A, et al. Aberrant lck Signal via CD28 Costimulation augments Antigen-Specific functionality and Tumor Control by Redirected T Cells with PD-1 blockade in Humanized mice. Clin Trial Clin Cancer Res. 2018;24:3981–93. https://doi.org/10.1158/1078-0432.CCR-17-1788.CrossRefPubMed

83.

Wang X, Yang X, Zhang C, et al. Tumor cell-intrinsic PD-1 receptor is a Tumor suppressor and mediates resistance to PD-1 blockade therapy. Proc Natl Acad Sci U S A. 2020;117:6640–50. https://doi.org/10.1073/pnas.192144511.CrossRefPubMedPubMedCentral

84.

Edinger M, Cao Y, Verneris MR, et al. Revealing Lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood. 2003;101:640–8. https://doi.org/10.1182/blood-2002-06-1751.CrossRefPubMed

85.

Wu X, Sharma A, Oldenburg J, et al. NKG2D Engagement alone is sufficient to Activate Cytokine-Induced Killer cells while 2B4 only provides limited coactivation. Front Immunol. 2021;12:731767. https://doi.org/10.3389/fimmu.2021.731767. Published online 2021 Oct 7.CrossRefPubMedPubMedCentral

86.

Verneis MR, Kornacker M, Mailänder V, Negrin RS. Resistance of ex vivo expanded CD3⁺CD56⁺ T cells to Fas-mediated apoptosis. Cancer Immunol Immunother. 2000;49(6):335–45. https://doi.org/10.1007/s002620000111.CrossRef

87.

Cappuzzelloa E, Tosia A, Zanovelloa P, et al. Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. Oncoimmunology. 2016;5:e1199311. https://doi.org/10.1080/2162402X.2016.1199311.CrossRef

88.

Zhang L, Wang J, Wei F, et al. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell Lung cancer patients. Oncotarget. 2016;7:43604–15. https://doi.org/10.18632/oncotarget.9871.CrossRefPubMedPubMedCentral

89.

Han Y, Mu D, Liu T, et al. Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell Lung cancer: a preliminary study. Thorac Cancer. 2021;12:145–52. https://doi.org/10.1111/1759-7714.13731.CrossRefPubMed

90.

Chen CL, Pan QZ, Weng DS, et al. Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. Oncoimmunology. 2018;7:e1417721. https://doi.org/10.1080/2162402X.2017.1417721.CrossRefPubMedPubMedCentral

91.

Wang Z, Liu X, Till B, Sun M, Li X, Gao Q. Combination of Cytokine-Induced Killer cells and programmed cell Death-1 Blockade Works synergistically to enhance therapeutic efficacy in metastatic renal cell carcinoma and Non-small Cell Lung Cancer. Front Immunol. 2018;9:1513. https://doi.org/10.3389/fimmu.2018.01513.CrossRefPubMedPubMedCentral

92.

Zhou L, Xiong Y, Wang Y, et al. A phase IB Trial of Autologous Cytokine-Induced Killer cells in combination with sintilimab, monoclonal antibody against programmed cell Death-1, plus Chemotherapy in patients with Advanced Non-small-cell Lung Cancer. Clin Lung Cancer. 2022;23(8):709–19. https://doi.org/10.1016/j.cllc.2022.07.009.CrossRefPubMed

93.

Mankor JM, Disselhorst MJ, Poncin M, et al. Efficacy of nivolumab and ipilimumab in patients with malignant pleural Mesothelioma is related to a subtype of effector memory cytotoxic T cells: translational evidence from two clinical trials. EBioMedicine. 2020;62:103040. https://doi.org/10.1016/j.ebiom.2020.103040.CrossRefPubMedPubMedCentral

94.

John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19:5636–46. https://doi.org/10.1158/1078-0432.CCR-13-0458.CrossRefPubMed

95.

John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology. 2013;2:e26286. https://doi.org/10.4161/onci.26286.CrossRefPubMedPubMedCentral

96.

Liu M, Wang X, Li W, et al. Targeting PD-L1 in non-small cell Lung cancer using CAR T cells. Oncogenesis. 2020;9:72. https://doi.org/10.1038/s41389-020-00257-z.CrossRefPubMedPubMedCentral

97.

Li S, Siriwon N, Zhang X, et al. Enhanced Cancer Immunotherapy by chimeric Antigen receptor–modified T cells Engineered to secrete checkpoint inhibitors. Clin Cancer Res. 2017;23:6982–92. https://doi.org/10.1158/1078-0432.CrossRefPubMed

98.

Tokatlian T, Asuelime GE, Mock JY, et al. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills Tumor cells. J Immunother Cancer. 2022;10:e003826. https://doi.org/10.1136/jitc-2021-003826.CrossRefPubMedPubMedCentral

99.

Ghosn M, Cheema W, Zhu A, et al. Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial. Lung Cancer. 2022;165:1–9. https://doi.org/10.1016/j.lungcan.2022.01.003.CrossRefPubMed

100.

Chen S, Lin Y, Zhong S, et al. Anti-MUC1 CAR-T cells combined with PD-1 knockout engineered T cells for patients with non-small cell Lung cancer (NSCLC): a pilot study. Ann Oncol. 2018;29(Supplement 10):x11–6. https://doi.org/10.1093/annonc/mdy485.CrossRef

101.

Byers LA, Chiappori A, Smit MAD. Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell Lung cancer (SCLC). J Clin Oncol. 2019;37:TPS8576. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS8576.CrossRef

102.

Zhong S, Cui Y, Liu Q, Chen S. CAR-T cell therapy for Lung Cancer: a Promising but Challenging Future. J Thorac Dis. 2020;12:4516–21. https://doi.org/10.21037/jtd.2020.03.118.CrossRefPubMedPubMedCentral

103.

Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-Cell therapy. Mol Ther Oncolytics. 2016;3:16011. https://doi.org/10.1038/mto.2016.11.CrossRefPubMedPubMedCentral

104.

Owen DH, Giffin MJ, Bailis JM, et al. DLL3: an emerging target in small cell Lung cancer. J Hematol Oncol. 2019;12:61. https://doi.org/10.1186/s13045-019-0745-2.CrossRefPubMedPubMedCentral

105.

Chen X, Amar N, Zhu Y, et al. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell Lung cancer growth. J Immunother Cancer. 2020;8:e000785. https://doi.org/10.1136/jitc-2020-000785.CrossRefPubMedPubMedCentral

106.

Adusumilli PS, Zauderer MG, Rivière I, et al. A phase I Trial of Regional Mesothelin-targeted CAR T-cell therapy in patients with malignant Pleural Disease, in combination with the Anti-PD-1 Agent Pembrolizumab. Cancer Discov. 2021;11:2748–63. https://doi.org/10.1158/2159-8290.CD-21-0407.CrossRefPubMedPubMedCentral

107.

Liu Z, Xia Y, Li L, Sun Y, Lin Z, Rong L, et al. Abstract CT134: non-viral mesothelin-targeted CAR-T cells armored with IFNg-induced secretion of PD-1 nanobody in treatment of malignant Mesothelioma in phase I clinical trial. Cancer Res. 2023;83(8Supplement):CT134. https://doi.org/10.1158/1538-7445.AM2023-CT134.CrossRef

108.

Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18:2188–98.CrossRefPubMedPubMedCentral

109.

Siegers GM, Dhamko H, Wang XH, et al. Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells. Cytotherapy. 2011;13:753–64. https://doi.org/10.3109/14653249.2011.553595.CrossRefPubMed

110.

Davey MS, Willcox CR, Baker AT, et al. Recasting human Vδ1 lymphocytes in an adaptive role. Trends Immunol. 2018;39:446–59. https://doi.org/10.1016/j.it.2018.03.003.CrossRefPubMedPubMedCentral

111.

Makkouk A, Yang XC, Barca T, et al. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. J Immunother Cancer. 2021;9(12):e003441. https://doi.org/10.1136/jitc-2021-003441.CrossRefPubMedPubMedCentral

112.

Sakamoto M, Nakajima J, Murakawa T, et al. Adoptive immunotherapy for advanced non-small cell Lung cancer using zoledronate-expanded γδ T cells: a phase I clinical study. J Immunother. 2011;34:202–11. https://doi.org/10.1097/CJI.0b013e318207ecfb.CrossRefPubMed

113.

Kakimi K, Matsushita H, Masuzawa K, et al. Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell Lung cancer: a multicenter, open-label, single-arm, phase 2 study. J Immunother Cancer. 2020;8:e001185. https://doi.org/10.1136/jitc-2020-001185.CrossRefPubMedPubMedCentral

114.

Bhat SA, Vedpathak DM, Chiplunkar SV. Checkpoint blockade rescues the repressive effect of histone deacetylases inhibitors on γδ T cell function. Front Immunol. 2018;9:1615. https://doi.org/10.3389/fimmu.2018.01615.CrossRefPubMedPubMedCentral

115.

Peters C, Oberg HH, Kabelitz D, Wesch D. Phenotype and regulation of immunosuppressive Vδ2-expressing γδ T cells. Cell Mol Life Sci. 2014;71(10):1943–60. https://doi.org/10.1007/s00018-013-1467-1.CrossRefPubMed

116.

Bezombes C, Rossi C, Gravelle P, et al. Boosting Gamma Delta T cells-mediated ADCC by PD-1 blockade in Follicular Lymphoma. Blood. 2018;132(Supplement 1):5381. https://doi.org/10.1182/blood-2018-99-112404.CrossRef

117.

Shinchi Y, Komohara Y, Yonemitsu K, et al. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: a retrospective study by double immunohistochemistry. Cancer Sci. 2019;110:2711–21. https://doi.org/10.1111/cas.14128.CrossRefPubMedPubMedCentral

118.

Takamori S, Takada K, Azuma K, et al. Prognostic impact of programmed death-ligand 2 expression in primary lung adenocarcinoma patients. Ann Surg Oncol. 2019;26:1916–24. https://doi.org/10.1245/s10434-019-07231-z.CrossRefPubMed

119.

Matsubara T, Takada K, Azuma K, et al. A clinicopathological and prognostic analysis of PD-L2 expression in surgically resected primary lung squamous cell carcinoma. Ann Surg Oncol. 2019;26:1925–33. https://doi.org/10.1245/s10434-019-07257-3.CrossRefPubMed

120.

Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261–8. https://doi.org/10.1038/85330.CrossRefPubMed

121.

Markham A, Duggan S. Cemiplimab: First Global approval. Drugs. 2018;78:1841–6. https://doi.org/10.1007/s40265-018-1012-5.CrossRefPubMed

122.

Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell Lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397:592–604. https://doi.org/10.1016/S0140-6736(21)00228-2.CrossRefPubMed

123.

Moreno V, Garrido P, Papadopoulos KP, et al. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell Lung cancer (NSCLC): data from the phase 1 NSCLC expansion cohort. Lung Cancer. 2021;155:151–5. https://doi.org/10.1016/j.lungcan.2021.02.034.CrossRefPubMed

124.

Tsay JJ, Wu BG, Sulaiman I, et al. Lower airway dysbiosis affects Lung cancer progression. Cancer Discov. 2021;11:293–307. https://doi.org/10.1158/2159-8290.CD-20-0263.CrossRefPubMed

125.

Zitvogel L, Kroemer G. Lower Airway dysbiosis exacerbates Lung cancer. Cancer Discov. 2021;11:224–6. https://doi.org/10.1158/2159-8290.CD-20-1641.CrossRefPubMed

126.

Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–7. https://doi.org/10.1126/science.aan3706.CrossRefPubMed

127.

Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell Lung cancer. Ann Oncol. 2018;29:1437–44. https://doi.org/10.1093/annonc/mdy103.CrossRefPubMedPubMedCentral

128.

Masuhiro K, Tamiya M, Fujimoto K, et al. Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in Lung cancer. JCI Insight. 2022;7:e157915. https://doi.org/10.1172/jci.insight.157915.CrossRefPubMedPubMedCentral

129.

Ochi N, Ichihara E, Takigawa N, et al. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell Lung cancer differ based on PD-L1 expression. Eur J Cancer. 2021;149:73–81. https://doi.org/10.1016/j.ejca.2021.02.040.CrossRefPubMed

130.

Qiao DR, Cheng JY, Yan WQ, et al. PD-L1/PD-1 blockage enhanced the cytotoxicity of natural killer cell on the non-small cell Lung cancer (NSCLC) by granzyme B secretion. Clin Transl Oncol. 2023;25:2373–83. https://doi.org/10.1007/s12094-023-03120-w.CrossRefPubMedPubMedCentral

Title: Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer
Authors: Yutao Li
Amit Sharma
Ingo G.H. Schmidt-Wolf
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: NSCLC
NSCLC
Lung Cancer
Lung Cancer
Lung Cancer
SCLC
SCLC
Cytokines
Published in: Molecular Cancer / Issue 1/2024
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/s12943-023-01926-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments

Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome

A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation

Correction: Hsa_circ_001680 affects the proliferation and migration of CRC and mediates its chemoresistance by regulating BMI1 through miR-340

The DNA damage sensor ATM kinase interacts with the p53 mRNA and guides the DNA damage response pathway

Discrimination of pancreato-biliary cancer and pancreatitis patients by non-invasive liquid biopsy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer